Revisão de evidência atual | Fluvoxamina para tratamento precoce da infecção por SARS-CoV-2.

Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence – Drugs

Conteúdos relacionados:

RCT: Early treatment with fluvoxamine reduced the risk of emergency care and hospitalization among patients with COVID-19.

[Preprint] RCT: Fluvoxamine reduced the risk for ER visits and hospitalization among patients with Covid-19.

Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).

Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19